ACHN
Achillion Pharmaceuticals Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| 03-06-2019 | 03-06-2019 | 03-06-2019 | 03-06-2019 | 03-06-2019 | 03-06-2019 | 03-06-2019 | 03-06-2019 | 03-06-2019 | 03-06-2019 | 03-06-2019 | 03-06-2019 | 03-06-2019 | 03-06-2019 | 03-06-2019 | 03-06-2019 | 03-06-2019 | 03-06-2019 | 03-06-2019 | 03-06-2019 | 03-06-2019 | 03-06-2019 | 03-06-2019 | 03-06-2019 | 03-06-2019 | 03-06-2019 | 03-06-2019 | 03-06-2019 | 11-07-2018 | 08-08-2018 | 05-02-2018 | 02-22-2018 | 11-01-2017 | 08-08-2017 after market close | 05-04-2017 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actual EPS | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.15 | -0.17 | -0.14 | -0.16 | -0.15 |
| Consensus EPS | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.14 | -0.13 | -0.14 | -0.15 | -0.18 | -0.16 | -0.08 |
| Estimated EPS | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.15 | -0.14 | -0.13 | -0.14 | -0.15 | -0.18 | -0.16 | -0.08 |
| Number of Estimates | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 4 |
| EPS Surprise | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.02 | $0.01 | -$0.01 | -$0.02 | $0.04 | -$0.07 |
Stats
Summary
Achillion Pharmaceuticals Inc is a biotechnology company. It is engaged in the discovery and development of innovative small-molecule drug therapies for infectious diseases and immune system disorders.
Market Cap: 396 Million
Primary Exchange: Nasdaq Global Select
Website: http://www.achillion.com
Shares Outstanding: 138 Million
Float: 138 Million
Dividend: 0.0 (0.0%)
Beta: 1.356592
Sector: Healthcare
Industry: Biotechnology
Short Interest (Jan 12, 2018): 6.08 Million
Ethical Flags
Longest drawdown: 1110 trading days
From: 2015-01-23 To: 2019-06-12
Lowest Point:
XBI: Biotech Performance And Valuation Update - June 2019
via: SeekingAlpha at 2019-06-03 05:30:25:000
SPDR Biotech ETF (NYSE: XBI ) provides investors diversified exposure to one of the most exciting industries in the market. Diversified is a relative term here because biotechnology companies, particularly those that are still in early stages of drug development, are often times the riskie… read more...
XBI: Biotech Performance And Valuation Update - June 2019
via: SeekingAlpha at 2019-06-03 05:30:25:000
SPDR Biotech ETF (NYSE: XBI ) provides investors diversified exposure to one of the most exciting industries in the market. Diversified is a relative term here because biotechnology companies, particularly those that are still in early stages of drug development, are often times the riskie… read more...
XBI: Biotech Performance And Valuation Update - June 2019
via: SeekingAlpha at 2019-06-03 05:30:25:000
SPDR Biotech ETF (NYSE: XBI ) provides investors diversified exposure to one of the most exciting industries in the market. Diversified is a relative term here because biotechnology companies, particularly those that are still in early stages of drug development, are often times the riskie… read more...
Achillion Pharmaceuticals Reports Positive PNH Data, But The Market Doesn't Care
via: SeekingAlpha at 2019-05-29 08:27:33:000
Achillion Pharmaceuticals ( ACHN ) has trended lower over the last two weeks despite reporting positive phase 2 results of ACH-4471 in combination with Soliris in PNH patients. The results look encouraging, but investors are either concerned with two safety events that resolved with patients… read more...
Achillion Pharmaceuticals Reports Positive PNH Data, But The Market Doesn't Care
via: SeekingAlpha at 2019-05-29 08:27:33:000
Achillion Pharmaceuticals ( ACHN ) has trended lower over the last two weeks despite reporting positive phase 2 results of ACH-4471 in combination with Soliris in PNH patients. The results look encouraging, but investors are either concerned with two safety events that resolved with patients… read more...
Achillion Pharmaceuticals Reports Positive PNH Data, But The Market Doesn't Care
via: SeekingAlpha at 2019-05-29 08:27:33:000
Achillion Pharmaceuticals ( ACHN ) has trended lower over the last two weeks despite reporting positive phase 2 results of ACH-4471 in combination with Soliris in PNH patients. The results look encouraging, but investors are either concerned with two safety events that resolved with patients… read more...
ACHN and CRAY among premarket gainers
via: SeekingAlpha at 2019-05-17 05:20:12:000
Cray (NASDAQ: CRAY ) +17% on being acquired by HPE. More news on: Cray Inc., Outlook Therapeutics, Inc., DropCar, Inc., Stocks on the move, Read more … read more...
ACHN and CRAY among premarket gainers
via: SeekingAlpha at 2019-05-17 05:20:12:000
Cray (NASDAQ: CRAY ) +17% on being acquired by HPE. More news on: Cray Inc., Outlook Therapeutics, Inc., DropCar, Inc., Stocks on the move, Read more … read more...
ACHN and CRAY among premarket gainers
via: SeekingAlpha at 2019-05-17 05:20:12:000
Cray (NASDAQ: CRAY ) +17% on being acquired by HPE. More news on: Cray Inc., Outlook Therapeutics, Inc., DropCar, Inc., Stocks on the move, Read more … read more...
ACHN and CRAY among premarket gainers
via: SeekingAlpha at 2019-05-17 05:20:12:000
Cray (NASDAQ: CRAY ) +17% on being acquired by HPE. More news on: Cray Inc., Outlook Therapeutics, Inc., DropCar, Inc., Stocks on the move, Read more … read more...
ACHN and CRAY among premarket gainers
via: SeekingAlpha at 2019-05-17 05:20:12:000
Cray (NASDAQ: CRAY ) +17% on being acquired by HPE. More news on: Cray Inc., Outlook Therapeutics, Inc., DropCar, Inc., Stocks on the move, Read more … read more...
Achillion's ACH-4471 shows encouraging action in PNH study; shares ahead 7% premarket
via: SeekingAlpha at 2019-05-17 03:53:29:000
Achillion Pharmaceuticals (NASDAQ: ACHN ) is up 7% premarket on light volume in response to preliminary data from a Phase 2 clinical trial evaluating factor D inhibitor ACH-4471 in patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare inherited disorder characterized … read more...
Achillion's ACH-4471 shows encouraging action in PNH study; shares ahead 7% premarket
via: SeekingAlpha at 2019-05-17 03:53:29:000
Achillion Pharmaceuticals (NASDAQ: ACHN ) is up 7% premarket on light volume in response to preliminary data from a Phase 2 clinical trial evaluating factor D inhibitor ACH-4471 in patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare inherited disorder characterized … read more...
Achillion's ACH-4471 shows encouraging action in PNH study; shares ahead 7% premarket
via: SeekingAlpha at 2019-05-17 03:53:29:000
Achillion Pharmaceuticals (NASDAQ: ACHN ) is up 7% premarket on light volume in response to preliminary data from a Phase 2 clinical trial evaluating factor D inhibitor ACH-4471 in patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare inherited disorder characterized … read more...
Achillion's ACH-4471 shows encouraging action in PNH study; shares ahead 7% premarket
via: SeekingAlpha at 2019-05-17 03:53:29:000
Achillion Pharmaceuticals (NASDAQ: ACHN ) is up 7% premarket on light volume in response to preliminary data from a Phase 2 clinical trial evaluating factor D inhibitor ACH-4471 in patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare inherited disorder characterized … read more...
Achillion's ACH-4471 shows encouraging action in PNH study; shares ahead 7% premarket
via: SeekingAlpha at 2019-05-17 03:53:29:000
Achillion Pharmaceuticals (NASDAQ: ACHN ) is up 7% premarket on light volume in response to preliminary data from a Phase 2 clinical trial evaluating factor D inhibitor ACH-4471 in patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare inherited disorder characterized … read more...
BioCryst Pharmaceuticals: BCX7353 Phase 3 Results To Make Or Break This Story
via: SeekingAlpha at 2019-05-15 09:42:10:000
BioCryst Pharmaceuticals ( BCRX ) caught my eye recently because of the company advancing an oral factor D inhibitor into the clinic BCX9930. Complement inhibition is an area of interest for me and Ive recently written an article on Achillion Pharmaceuticals ( ACHN ) w… read more...
BioCryst Pharmaceuticals: BCX7353 Phase 3 Results To Make Or Break This Story
via: SeekingAlpha at 2019-05-15 09:42:10:000
BioCryst Pharmaceuticals ( BCRX ) caught my eye recently because of the company advancing an oral factor D inhibitor into the clinic BCX9930. Complement inhibition is an area of interest for me and Ive recently written an article on Achillion Pharmaceuticals ( ACHN ) w… read more...
Achillion Pharmaceuticals EPS in-line
via: SeekingAlpha at 2019-05-09 02:20:22:000
Achillion Pharmaceuticals (NASDAQ: ACHN ): Q1 GAAP EPS of -$0.14 in-line. More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Achillion Pharmaceuticals EPS in-line
via: SeekingAlpha at 2019-05-09 02:20:22:000
Achillion Pharmaceuticals (NASDAQ: ACHN ): Q1 GAAP EPS of -$0.14 in-line. More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Achillion Pharmaceuticals EPS in-line
via: SeekingAlpha at 2019-05-09 02:20:22:000
Achillion Pharmaceuticals (NASDAQ: ACHN ): Q1 GAAP EPS of -$0.14 in-line. More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
ANET, CTSH and FTNT among premarket losers
via: SeekingAlpha at 2019-05-03 05:12:06:000
Diffusion Pharmaceuticals (NASDAQ: DFFN ) -20% . More news on: Diffusion Pharmaceuticals Inc., Arista Networks, Inc., Appian Corporation, Stocks on the move, Read more … read more...
ANET, CTSH and FTNT among premarket losers
via: SeekingAlpha at 2019-05-03 05:12:06:000
Diffusion Pharmaceuticals (NASDAQ: DFFN ) -20% . More news on: Diffusion Pharmaceuticals Inc., Arista Networks, Inc., Appian Corporation, Stocks on the move, Read more … read more...
ANET, CTSH and FTNT among premarket losers
via: SeekingAlpha at 2019-05-03 05:12:06:000
Diffusion Pharmaceuticals (NASDAQ: DFFN ) -20% . More news on: Diffusion Pharmaceuticals Inc., Arista Networks, Inc., Appian Corporation, Stocks on the move, Read more … read more...
ANET, CTSH and FTNT among premarket losers
via: SeekingAlpha at 2019-05-03 05:12:06:000
Diffusion Pharmaceuticals (NASDAQ: DFFN ) -20% . More news on: Diffusion Pharmaceuticals Inc., Arista Networks, Inc., Appian Corporation, Stocks on the move, Read more … read more...
ANET, CTSH and FTNT among premarket losers
via: SeekingAlpha at 2019-05-03 05:12:06:000
Diffusion Pharmaceuticals (NASDAQ: DFFN ) -20% . More news on: Diffusion Pharmaceuticals Inc., Arista Networks, Inc., Appian Corporation, Stocks on the move, Read more … read more...
Barclays sees 17% upside in Bristol-Myers in premarket analyst action
via: SeekingAlpha at 2019-05-03 03:09:11:000
Bristol-Myers Squibb (NYSE: BMY ) upgraded to Overweight with a $55 (17% upside) price target at Barclays. Shares up 1% premarket. More news on: Bristol-Myers Squibb Company, Acceleron Pharma Inc., Incyte Corporation, Healthcare stocks news, Stocks on the move, , Read more … read more...
Barclays sees 17% upside in Bristol-Myers in premarket analyst action
via: SeekingAlpha at 2019-05-03 03:09:11:000
Bristol-Myers Squibb (NYSE: BMY ) upgraded to Overweight with a $55 (17% upside) price target at Barclays. Shares up 1% premarket. More news on: Bristol-Myers Squibb Company, Acceleron Pharma Inc., Incyte Corporation, Healthcare stocks news, Stocks on the move, , Read more … read more...
Barclays sees 17% upside in Bristol-Myers in premarket analyst action
via: SeekingAlpha at 2019-05-03 03:09:11:000
Bristol-Myers Squibb (NYSE: BMY ) upgraded to Overweight with a $55 (17% upside) price target at Barclays. Shares up 1% premarket. More news on: Bristol-Myers Squibb Company, Acceleron Pharma Inc., Incyte Corporation, Healthcare stocks news, Stocks on the move, , Read more … read more...
Barclays sees 17% upside in Bristol-Myers in premarket analyst action
via: SeekingAlpha at 2019-05-03 03:09:11:000
Bristol-Myers Squibb (NYSE: BMY ) upgraded to Overweight with a $55 (17% upside) price target at Barclays. Shares up 1% premarket. More news on: Bristol-Myers Squibb Company, Acceleron Pharma Inc., Incyte Corporation, Healthcare stocks news, Stocks on the move, , Read more … read more...
Barclays sees 17% upside in Bristol-Myers in premarket analyst action
via: SeekingAlpha at 2019-05-03 03:09:11:000
Bristol-Myers Squibb (NYSE: BMY ) upgraded to Overweight with a $55 (17% upside) price target at Barclays. Shares up 1% premarket. More news on: Bristol-Myers Squibb Company, Acceleron Pharma Inc., Incyte Corporation, Healthcare stocks news, Stocks on the move, , Read more … read more...
Achillion achieves enrollment milestone in phase 2 trials for C3G
via: SeekingAlpha at 2019-04-03 04:47:03:000
Achillion Pharmaceuticals (NASDAQ: ACHN ) has enrolled 23 patients in Phase 2 ACH-4471 six and 12-month clinical trials for patients with C3 glomerulopathy (C3G), a disease affecting the kidney for which there is no approved therapy. More news on: Achillion Pharmaceuticals, Inc., Healthc… read more...
Achillion achieves enrollment milestone in phase 2 trials for C3G
via: SeekingAlpha at 2019-04-03 04:47:03:000
Achillion Pharmaceuticals (NASDAQ: ACHN ) has enrolled 23 patients in Phase 2 ACH-4471 six and 12-month clinical trials for patients with C3 glomerulopathy (C3G), a disease affecting the kidney for which there is no approved therapy. More news on: Achillion Pharmaceuticals, Inc., Healthc… read more...
Achillion achieves enrollment milestone in phase 2 trials for C3G
via: SeekingAlpha at 2019-04-03 04:47:03:000
Achillion Pharmaceuticals (NASDAQ: ACHN ) has enrolled 23 patients in Phase 2 ACH-4471 six and 12-month clinical trials for patients with C3 glomerulopathy (C3G), a disease affecting the kidney for which there is no approved therapy. More news on: Achillion Pharmaceuticals, Inc., Healthc… read more...
Achillion Pharmaceuticals: The Promise Of Alternative Pathway Inhibition
via: SeekingAlpha at 2019-03-20 05:49:27:000
Ive been following Achillion Pharmaceuticals ( ACHN ) for quite some time, but became more interested after the company reported positive results of its factor D inhibitor ACH-4471 in two rare diseases PNH and C3G. The problem with PNH is that the results arent goo… read more...
Achillion Pharmaceuticals: The Promise Of Alternative Pathway Inhibition
via: SeekingAlpha at 2019-03-20 05:49:27:000
Ive been following Achillion Pharmaceuticals ( ACHN ) for quite some time, but became more interested after the company reported positive results of its factor D inhibitor ACH-4471 in two rare diseases PNH and C3G. The problem with PNH is that the results arent goo… read more...
Achillion Pharmaceuticals: The Promise Of Alternative Pathway Inhibition
via: SeekingAlpha at 2019-03-20 05:49:27:000
Ive been following Achillion Pharmaceuticals ( ACHN ) for quite some time, but became more interested after the company reported positive results of its factor D inhibitor ACH-4471 in two rare diseases PNH and C3G. The problem with PNH is that the results arent goo… read more...
Achillion Pharmaceuticals (ACHN) Presents At Barclays Global Healthcare Conference - Slideshow
via: SeekingAlpha at 2019-03-14 10:30:52:000
The following slide deck was published by Achillion Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Achillion Pharmaceuticals (ACHN) Presents At Barclays Global Healthcare Conference - Slideshow
via: SeekingAlpha at 2019-03-14 10:30:52:000
The following slide deck was published by Achillion Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Achillion Pharmaceuticals (ACHN) Presents At Barclays Global Healthcare Conference - Slideshow
via: SeekingAlpha at 2019-03-14 10:30:52:000
The following slide deck was published by Achillion Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Achillion Pharmaceuticals beats by $0.03
via: SeekingAlpha at 2019-03-07 01:08:10:000
Achillion Pharmaceuticals (NASDAQ: ACHN ): Q4 GAAP EPS of -$0.12 beats by $0.03. More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Achillion Pharmaceuticals beats by $0.03
via: SeekingAlpha at 2019-03-07 01:08:10:000
Achillion Pharmaceuticals (NASDAQ: ACHN ): Q4 GAAP EPS of -$0.12 beats by $0.03. More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Achillion Pharmaceuticals beats by $0.03
via: SeekingAlpha at 2019-03-07 01:08:10:000
Achillion Pharmaceuticals (NASDAQ: ACHN ): Q4 GAAP EPS of -$0.12 beats by $0.03. More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Achillion Pharmaceuticals (ACHN) Presents At SVB Leerink 8th Global Healthcare Conference - Slideshow
via: SeekingAlpha at 2019-02-28 15:43:33:000
The following slide deck was published by Achillion Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Achillion Pharmaceuticals (ACHN) Presents At SVB Leerink 8th Global Healthcare Conference - Slideshow
via: SeekingAlpha at 2019-02-28 10:43:33:000
The following slide deck was published by Achillion Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Achillion Pharmaceuticals (ACHN) Presents At SVB Leerink 8th Global Healthcare Conference - Slideshow
via: SeekingAlpha at 2019-02-28 10:43:33:000
The following slide deck was published by Achillion Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Momentum Strategies That Continue To Dominate Through January
via: SeekingAlpha at 2019-01-17 16:24:11:000
The 20 stocks in the Premium Portfolio from my membership service that draws from a wide range of different models in the financial literature has surged to 15% gains through January. These gains again appear to be primarily based on the strength of momentum and forensic negative stock selecti… read more...
Momentum Strategies That Continue To Dominate Through January
via: SeekingAlpha at 2019-01-17 16:24:11:000
The 20 stocks in the Premium Portfolio from my membership service that draws from a wide range of different models in the financial literature has surged to 15% gains through January. These gains again appear to be primarily based on the strength of momentum and forensic negative stock selecti… read more...
Momentum Strategies That Continue To Dominate Through January
via: SeekingAlpha at 2019-01-17 16:24:11:000
The 20 stocks in the Premium Portfolio from my membership service that draws from a wide range of different models in the financial literature has surged to 15% gains through January. These gains again appear to be primarily based on the strength of momentum and forensic negative stock selecti… read more...
Achillion Pharmaceuticals (ACHN) Guidance Call - Slideshow
via: SeekingAlpha at 2018-12-18 13:01:57:000
The following slide deck was published by Achillion Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Achillion Pharmaceuticals (ACHN) Guidance Call - Slideshow
via: SeekingAlpha at 2018-12-18 13:01:57:000
The following slide deck was published by Achillion Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Achillion Pharmaceuticals (ACHN) Guidance Call - Slideshow
via: SeekingAlpha at 2018-12-18 13:01:57:000
The following slide deck was published by Achillion Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Healthcare & Tech leads midday movers
via: SeekingAlpha at 2018-12-18 12:53:51:000
Gainers: Marin Software (NASDAQ: MRIN ) +45% .HyreCar (NASDAQ: HYRE ) +26% . The Lovesac (NASDAQ: LOVE ) +19% . Electrameccanica Vehicles (NASDAQ: SOLO ) +17% . The Meet Group (NASDAQ: MEET ) +16% . Tyme Technologies (NASDAQ: TYME ) +12% . Diebold Nixdorf (NYSE: DBD ) +1… read more...
Healthcare & Tech leads midday movers
via: SeekingAlpha at 2018-12-18 12:53:51:000
Gainers: Marin Software (NASDAQ: MRIN ) +45% .HyreCar (NASDAQ: HYRE ) +26% . The Lovesac (NASDAQ: LOVE ) +19% . Electrameccanica Vehicles (NASDAQ: SOLO ) +17% . The Meet Group (NASDAQ: MEET ) +16% . Tyme Technologies (NASDAQ: TYME ) +12% . Diebold Nixdorf (NYSE: DBD ) +1… read more...
Healthcare & Tech leads midday movers
via: SeekingAlpha at 2018-12-18 12:53:51:000
Gainers: Marin Software (NASDAQ: MRIN ) +45% .HyreCar (NASDAQ: HYRE ) +26% . The Lovesac (NASDAQ: LOVE ) +19% . Electrameccanica Vehicles (NASDAQ: SOLO ) +17% . The Meet Group (NASDAQ: MEET ) +16% . Tyme Technologies (NASDAQ: TYME ) +12% . Diebold Nixdorf (NYSE: DBD ) +1… read more...
RIOT, MRIN among premarket gainers
via: SeekingAlpha at 2018-12-18 09:13:26:000
Marin Software (NASDAQ: MRIN ) +51% on Google revenue sharing deal , updated guidance. More news on: Marin Software, Tilray, Inc., Achillion Pharmaceuticals, Inc., Stocks on the move, , Read more … read more...
RIOT, MRIN among premarket gainers
via: SeekingAlpha at 2018-12-18 09:13:26:000
Marin Software (NASDAQ: MRIN ) +51% on Google revenue sharing deal , updated guidance. More news on: Marin Software, Tilray, Inc., Achillion Pharmaceuticals, Inc., Stocks on the move, , Read more … read more...
RIOT, MRIN among premarket gainers
via: SeekingAlpha at 2018-12-18 09:13:26:000
Marin Software (NASDAQ: MRIN ) +51% on Google revenue sharing deal , updated guidance. More news on: Marin Software, Tilray, Inc., Achillion Pharmaceuticals, Inc., Stocks on the move, , Read more … read more...
After Hours Gainers / Losers (12/17/2018)
via: SeekingAlpha at 2018-12-17 17:41:52:000
Top Gainers: PBYI +9.2% . SND +7.2% . BRY +3.6% . More news on: Puma Biotechnology, Inc., Smart Sand, Berry Petroleum Corp., Stocks on the move, , News on ETFs, Read more … read more...
Achillion up 2% after hours on positive ACH-4471 data
via: SeekingAlpha at 2018-12-17 16:19:41:000
Achillion Pharmaceuticals (NASDAQ: ACHN ) is up 2% after hours in response to its announcement of interim data from its Phase 2 studies of complement factor D inhibitor ACH-4471, alone and with a C5 inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 gl… read more...
Microcaps mostly among midday movers
via: SeekingAlpha at 2018-12-17 12:49:40:000
Gainers: Diffusion Pharmaceuticals (NASDAQ: DFFN ) +42% .NRC Group Holdings (NYSEMKT: NRCG ) +22% . Fidelity Southern (NASDAQ: LION ) +21% . HyreCar (NASDAQ: HYRE ) +18% . YRC Worldwide (NASDAQ: YRCW ) +19% . Axovant Sciences (NASDAQ: AXON ) +17% . AgeX Therapeutics (NYSE… read more...
Time To Connect The Dots (Stocks To Watch Podcast)
via: SeekingAlpha at 2018-12-16 08:04:21:000
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look … read more...
Stocks To Watch: Time To Connect The Dots
via: SeekingAlpha at 2018-12-15 09:12:29:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. There are two monster meetings on the agenda next week that could shake things up f… read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-12-14 09:54:28:000
Noteworthy events during the week of December 16 - 22 for healthcare investors. More news on: Innovate Biopharmaceuticals, Inc., Achillion Pharmaceuticals, Inc., ADMA Biologics Inc, Healthcare stocks news, , Read more … read more...
Achillion Pharmaceuticals: Overlooked Value Play Or Potential Trap?
via: SeekingAlpha at 2018-11-28 13:21:27:000
2018 Third Quarter Recap and Update Achillion Pharmaceuticals (NASDAQ: ACHN)) reported Q3 earnings November 7 th , 2018, with a mixed reaction from the market in the following week. Initially, the stock popped up to approximately $3/share but shortly after dropped to a low of around $2.60/… read more...
Achillion Pharmaceuticals: Overlooked Value Play Or Potential Trap?
via: SeekingAlpha at 2018-11-28 13:21:27:000
2018 Third Quarter Recap and Update Achillion Pharmaceuticals (NASDAQ: ACHN)) reported Q3 earnings November 7 th , 2018, with a mixed reaction from the market in the following week. Initially, the stock popped up to approximately $3/share but shortly after dropped to a low of around $2.60/… read more...
Achillion Pharmaceuticals: Overlooked Value Play Or Potential Trap?
via: SeekingAlpha at 2018-11-28 13:21:27:000
2018 Third Quarter Recap and Update Achillion Pharmaceuticals (NASDAQ: ACHN)) reported Q3 earnings November 7 th , 2018, with a mixed reaction from the market in the following week. Initially, the stock popped up to approximately $3/share but shortly after dropped to a low of around $2.60/… read more...
Achillion Pharmaceuticals beats by $0.02
via: SeekingAlpha at 2018-11-07 06:03:40:000
Achillion Pharmaceuticals (NASDAQ: ACHN ): Q3 GAAP EPS of -$0.12 beats by $0.02 . More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Achillion Pharmaceuticals beats by $0.02
via: SeekingAlpha at 2018-11-07 06:03:40:000
Achillion Pharmaceuticals (NASDAQ: ACHN ): Q3 GAAP EPS of -$0.12 beats by $0.02 . More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Achillion Pharmaceuticals beats by $0.02
via: SeekingAlpha at 2018-11-07 06:03:40:000
Achillion Pharmaceuticals (NASDAQ: ACHN ): Q3 GAAP EPS of -$0.12 beats by $0.02 . More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Ra Pharma's zilucoplan shows favorable PK profile in renal impairment patients, expanding potential clinical programs
via: SeekingAlpha at 2018-09-26 08:14:53:000
Results from a Phase 1b assessing the pharmacokinetics of Ra Pharmaceuticals' (NASDAQ: RARX ) RA101495 SC (zilucoplan) in patients with severe renal impairment showed a similar profile compared to healthy patients. There were no adverse events reported and the data indicate that no adjust… read more...
Ra Pharma's zilucoplan shows favorable PK profile in renal impairment patients, expanding potential clinical programs
via: SeekingAlpha at 2018-09-26 08:14:53:000
Results from a Phase 1b assessing the pharmacokinetics of Ra Pharmaceuticals' (NASDAQ: RARX ) RA101495 SC (zilucoplan) in patients with severe renal impairment showed a similar profile compared to healthy patients. There were no adverse events reported and the data indicate that no adjust… read more...
Ra Pharma's zilucoplan shows favorable PK profile in renal impairment patients, expanding potential clinical programs
via: SeekingAlpha at 2018-09-26 08:14:53:000
Results from a Phase 1b assessing the pharmacokinetics of Ra Pharmaceuticals' (NASDAQ: RARX ) RA101495 SC (zilucoplan) in patients with severe renal impairment showed a similar profile compared to healthy patients. There were no adverse events reported and the data indicate that no adjust… read more...
Achillion appoints Dr. Steven Zelenkofske as Chief Medical Officer
via: SeekingAlpha at 2018-08-21 06:18:52:000
Achillion Pharmaceuticals (NASDAQ: ACHN ) appoints Steven Zelenkofske, D.O. to the position of Executive Vice President and Chief Medical Officer, effective immediately. More news on: Achillion Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Achillion appoints Dr. Steven Zelenkofske as Chief Medical Officer
via: SeekingAlpha at 2018-08-21 06:18:52:000
Achillion Pharmaceuticals (NASDAQ: ACHN ) appoints Steven Zelenkofske, D.O. to the position of Executive Vice President and Chief Medical Officer, effective immediately. More news on: Achillion Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Achillion appoints Dr. Steven Zelenkofske as Chief Medical Officer
via: SeekingAlpha at 2018-08-21 06:18:52:000
Achillion Pharmaceuticals (NASDAQ: ACHN ) appoints Steven Zelenkofske, D.O. to the position of Executive Vice President and Chief Medical Officer, effective immediately. More news on: Achillion Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Achillion Pharmaceuticals beats by $0.01
via: SeekingAlpha at 2018-08-08 16:51:47:000
Achillion Pharmaceuticals (NASDAQ: ACHN ): Q2 EPS of -$0.12 beats by $0.01 . More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Achillion Pharmaceuticals beats by $0.01
via: SeekingAlpha at 2018-08-08 16:51:47:000
Achillion Pharmaceuticals (NASDAQ: ACHN ): Q2 EPS of -$0.12 beats by $0.01 . More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Achillion Pharmaceuticals beats by $0.01
via: SeekingAlpha at 2018-08-08 16:51:47:000
Achillion Pharmaceuticals (NASDAQ: ACHN ): Q2 EPS of -$0.12 beats by $0.01 . More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Week 29 Breakout Forecast: Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2018-07-15 02:25:07:000
Breakout Forecast Selections for Week 29: Market conditions continue with medium breakout momentum. The positive momentum gauge continues with another full week in yellow (medium) at 34 down from a value of 46 at the end of the prior week. The negative momentum gauge is unchanged from a… read more...
Week 29 Breakout Forecast: Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2018-07-15 02:25:07:000
Breakout Forecast Selections for Week 29: Market conditions continue with medium breakout momentum. The positive momentum gauge continues with another full week in yellow (medium) at 34 down from a value of 46 at the end of the prior week. The negative momentum gauge is unchanged from a… read more...
Week 29 Breakout Forecast: Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2018-07-15 02:25:07:000
Breakout Forecast Selections for Week 29: Market conditions continue with medium breakout momentum. The positive momentum gauge continues with another full week in yellow (medium) at 34 down from a value of 46 at the end of the prior week. The negative momentum gauge is unchanged from a… read more...
Midday Gainers / Losers (07/13/2018)
via: SeekingAlpha at 2018-07-13 12:37:51:000
Gainers: BIOC +73% . PIXY +55% . SNES +24% . GLMD +20% . ADXS +17% . CFMS +14% . IFRX +13% . ACHN +11% . RUBI +11% . ZGNX +11% . More news on: Biocept, Inc., ShiftPixy, SenesTech, Stocks on the move, , Read more … read more...
Midday Gainers / Losers (07/13/2018)
via: SeekingAlpha at 2018-07-13 12:37:51:000
Gainers: BIOC +73% . PIXY +55% . SNES +24% . GLMD +20% . ADXS +17% . CFMS +14% . IFRX +13% . ACHN +11% . RUBI +11% . ZGNX +11% . More news on: Biocept, Inc., ShiftPixy, SenesTech, Stocks on the move, , Read more … read more...
Achillion Is A Worthwhile Biotech Speculation
via: SeekingAlpha at 2018-07-12 12:51:34:000
Investment Thesis Achillion Pharmaceuticals ( ACHN ) is a high conviction speculative pick for us given the strong balance sheet, Orphan drug pipeline, and focus on core compounds which have shown potential for multiple applications. With the compelling research pipeline over the next 2-3 … read more...
Your Daily Pharma Scoop: Kamada Phase 3 Approved, Vivus Positive, IsoRay Down
via: SeekingAlpha at 2018-07-12 06:28:07:000
Stocks in News: KMDA, VVUS, CHMP on board with design of late-stage study of Kamada's inhaled AAT for AATD; shares up 4% premarket Discussion : Kamada Ltd. ( KMDA ) announced that EMA advisory group CHMP approved the general design of the Phase 3 clinical trial of inhaled alpha-1 anti… read more...
Achillion launches early-stage study of next-gen complement factor D inhibitor
via: SeekingAlpha at 2018-07-10 07:45:00:000
Dosing is underway in a 28-subject Phase 1 clinical trial assessing Achillion Pharmaceuticals' (NASDAQ: ACHN ) next-generation complement factor D inhibitor, ACH-5548, in healthy volunteers. More news on: Achillion Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Achillion launches early-stage study of next-gen complement factor D inhibitor
via: SeekingAlpha at 2018-07-10 07:45:00:000
Dosing is underway in a 28-subject Phase 1 clinical trial assessing Achillion Pharmaceuticals' (NASDAQ: ACHN ) next-generation complement factor D inhibitor, ACH-5548, in healthy volunteers. More news on: Achillion Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Achillion Pharmaceuticals - Biotech Gold For The Price Of Dirt
via: SeekingAlpha at 2018-07-09 12:45:57:000
Welcome to Achillion ( ACHN ) - I've been following the company for a bit, but only after the JNJ Hep C disaster, so I won't be painting much of a picture for that asset, nor times before it. Rather I want to focus on lead asset 4471 and their second-generation drugs. And the ridiculous amount… read more...
Institutional Top Ideas: EcoR1 Capital
via: SeekingAlpha at 2018-06-12 02:08:54:000
In the last entry of this series , we took a look at top ideas from Biotechnology Value Fund, a hedge fund with very high returns of late made even more impressive by their lower turnover and concentration in several positions without overweighting to an extreme as some funds do. Going forw… read more...
Institutional Top Ideas: EcoR1 Capital
via: SeekingAlpha at 2018-06-12 02:08:54:000
In the last entry of this series , we took a look at top ideas from Biotechnology Value Fund, a hedge fund with very high returns of late made even more impressive by their lower turnover and concentration in several positions without overweighting to an extreme as some funds do. Going forw… read more...
Institutional Top Ideas: EcoR1 Capital
via: SeekingAlpha at 2018-06-12 02:08:54:000
In the last entry of this series , we took a look at top ideas from Biotechnology Value Fund, a hedge fund with very high returns of late made even more impressive by their lower turnover and concentration in several positions without overweighting to an extreme as some funds do. Going forw… read more...
Institutional Top Ideas: EcoR1 Capital
via: SeekingAlpha at 2018-06-12 02:08:54:000
In the last entry of this series , we took a look at top ideas from Biotechnology Value Fund, a hedge fund with very high returns of late made even more impressive by their lower turnover and concentration in several positions without overweighting to an extreme as some funds do. Going forw… read more...
Institutional Top Ideas: EcoR1 Capital
via: SeekingAlpha at 2018-06-12 02:08:54:000
In the last entry of this series , we took a look at top ideas from Biotechnology Value Fund, a hedge fund with very high returns of late made even more impressive by their lower turnover and concentration in several positions without overweighting to an extreme as some funds do. Going forw… read more...
Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)
via: SeekingAlpha at 2018-05-31 09:04:00:000
This article is the second of two parts discussing Alexion Pharmaceuticals ( ALXN ) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXNs competition. I have previously reviewed a large number of ALXNs compet… read more...
Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)
via: SeekingAlpha at 2018-05-31 09:04:00:000
This article is the second of two parts discussing Alexion Pharmaceuticals ( ALXN ) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXNs competition. I have previously reviewed a large number of ALXNs compet… read more...
Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)
via: SeekingAlpha at 2018-05-31 09:04:00:000
This article is the second of two parts discussing Alexion Pharmaceuticals ( ALXN ) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXNs competition. I have previously reviewed a large number of ALXNs compet… read more...
Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)
via: SeekingAlpha at 2018-05-31 09:04:00:000
This article is the second of two parts discussing Alexion Pharmaceuticals ( ALXN ) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXNs competition. I have previously reviewed a large number of ALXNs compet… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-05-21 08:19:20:000
AMAG Pharmaceuticals (NASDAQ: AMAG ) initiated with Market Perform rating and $26 (5% upside) price target at Leerink. More news on: AMAG Pharmaceuticals, Inc., Achillion Pharmaceuticals, Inc., Sabra Healthcare REIT, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-05-21 08:19:20:000
AMAG Pharmaceuticals (NASDAQ: AMAG ) initiated with Market Perform rating and $26 (5% upside) price target at Leerink. More news on: AMAG Pharmaceuticals, Inc., Achillion Pharmaceuticals, Inc., Sabra Healthcare REIT, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-05-18 16:37:17:000
Noteworthy events during the week of May 20 - 26 for healthcare investors: More news on: uniQure N.V., Roche Holding Ltd ADR, BioMarin Pharmaceutical Inc., Healthcare stocks news, , Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-05-18 16:37:17:000
Noteworthy events during the week of May 20 - 26 for healthcare investors: More news on: uniQure N.V., Roche Holding Ltd ADR, BioMarin Pharmaceutical Inc., Healthcare stocks news, , Read more … read more...
Institutional Top Ideas Series: Opaleye Management
via: SeekingAlpha at 2018-05-17 01:52:55:000
In the last entry of this series, we took a look at top ideas from Ra Capital Management, the best performing fund weve come across so far with heavily concentrated positions in their top ideas. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...
Institutional Top Ideas Series: Opaleye Management
via: SeekingAlpha at 2018-05-17 01:52:55:000
In the last entry of this series, we took a look at top ideas from Ra Capital Management, the best performing fund weve come across so far with heavily concentrated positions in their top ideas. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...
Achillion Pharmaceuticals misses by $0.01
via: SeekingAlpha at 2018-05-02 09:07:27:000
Achillion Pharmaceuticals (NASDAQ: ACHN ): Q1 EPS of -$0.15 misses by $0.01 . Cash, cash equivalents, marketable securities and interest receivable of $308.4M Shares +0.53% PM. Press Release More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare … read more...
Achillion Pharmaceuticals misses by $0.01
via: SeekingAlpha at 2018-05-02 09:07:27:000
Achillion Pharmaceuticals (NASDAQ: ACHN ): Q1 EPS of -$0.15 misses by $0.01 . Cash, cash equivalents, marketable securities and interest receivable of $308.4M Shares +0.53% PM. Press Release More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare … read more...
Achillion Pharmaceuticals misses by $0.01
via: SeekingAlpha at 2018-05-02 09:07:27:000
Achillion Pharmaceuticals (NASDAQ: ACHN ): Q1 EPS of -$0.15 misses by $0.01 . Cash, cash equivalents, marketable securities and interest receivable of $308.4M Shares +0.53% PM. Press Release More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare … read more...
Achillion, Omeros, Ra Rx, Reata, Chemocentryx And Others In The IgA Nephropathy Space
via: SeekingAlpha at 2018-04-09 13:39:22:000
I began this article with the intent of an Achillion Pharmaceuticals ( ACHN ) focus. However, as I learned more about each of these 5 companies, I've decided to give an equal spotlight to each. I will preface the real reason for this renal-focused article is due to my own diagnosis of IgA neph… read more...
Achillion, Omeros, Ra Rx, Reata, Chemocentryx And Others In The IgA Nephropathy Space
via: SeekingAlpha at 2018-04-09 13:39:22:000
I began this article with the intent of an Achillion Pharmaceuticals ( ACHN ) focus. However, as I learned more about each of these 5 companies, I've decided to give an equal spotlight to each. I will preface the real reason for this renal-focused article is due to my own diagnosis of IgA neph… read more...
Achillion, Omeros, Ra Rx, Reata, Chemocentryx And Others In The IgA Nephropathy Space
via: SeekingAlpha at 2018-04-09 13:39:22:000
I began this article with the intent of an Achillion Pharmaceuticals ( ACHN ) focus. However, as I learned more about each of these 5 companies, I've decided to give an equal spotlight to each. I will preface the real reason for this renal-focused article is due to my own diagnosis of IgA neph… read more...
Week 14 Breakout Forecast: Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2018-03-31 09:55:20:000
Breakout Forecast Selections for Week 14: Market conditions continue with extreme volatility. The Market Momentum Gauge indicators are now a subscription based forecasting feature to help gauge the expected momentum conditions for the week ahead. The total return of the Breakout Stock select… read more...
Week 14 Breakout Forecast: Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2018-03-31 09:55:20:000
Breakout Forecast Selections for Week 14: Market conditions continue with extreme volatility. The Market Momentum Gauge indicators are now a subscription based forecasting feature to help gauge the expected momentum conditions for the week ahead. The total return of the Breakout Stock select… read more...
Week 14 Breakout Forecast: Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2018-03-31 09:55:20:000
Breakout Forecast Selections for Week 14: Market conditions continue with extreme volatility. The Market Momentum Gauge indicators are now a subscription based forecasting feature to help gauge the expected momentum conditions for the week ahead. The total return of the Breakout Stock select… read more...
Achillion Pharmaceuticals (ACHN) Presents At Barclays Global Healthcare Conference 2018 - Slideshow
via: SeekingAlpha at 2018-03-16 15:11:37:000
The following slide deck was published by Achillion Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Achillion Pharmaceuticals (ACHN) Presents At Barclays Global Healthcare Conference 2018 - Slideshow
via: SeekingAlpha at 2018-03-16 15:11:37:000
The following slide deck was published by Achillion Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Achillion Pharmaceuticals (ACHN) Presents At Barclays Global Healthcare Conference 2018 - Slideshow
via: SeekingAlpha at 2018-03-16 15:11:37:000
The following slide deck was published by Achillion Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Alexion's long-acting PNH candidate ALXN1210 on par with Soliris in late-stage study; shares up 11% premarket
via: SeekingAlpha at 2018-03-15 07:30:55:000
Alexion Pharmaceuticals (NASDAQ: ALXN ) is up 11% premarket on light volume in response to its announcement of successful results from a Phase 3 clinical trial assessing ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria (PNH). More news on: Alexion Pharmaceuticals… read more...
Alexion's long-acting PNH candidate ALXN1210 on par with Soliris in late-stage study; shares up 11% premarket
via: SeekingAlpha at 2018-03-15 07:30:55:000
Alexion Pharmaceuticals (NASDAQ: ALXN ) is up 11% premarket on light volume in response to its announcement of successful results from a Phase 3 clinical trial assessing ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria (PNH). More news on: Alexion Pharmaceuticals… read more...
Alexion's long-acting PNH candidate ALXN1210 on par with Soliris in late-stage study; shares up 11% premarket
via: SeekingAlpha at 2018-03-15 07:30:55:000
Alexion Pharmaceuticals (NASDAQ: ALXN ) is up 11% premarket on light volume in response to its announcement of successful results from a Phase 3 clinical trial assessing ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria (PNH). More news on: Alexion Pharmaceuticals… read more...
3 Things In Biotech You Should Learn Today: February 27, 2018
via: SeekingAlpha at 2018-02-28 08:00:00:000
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Arca Bio crushed on poor heart trial results Company: Arca Bio ( ABIO ) Therapy: Buci… read more...
3 Things In Biotech You Should Learn Today: February 27, 2018
via: SeekingAlpha at 2018-02-28 08:00:00:000
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Arca Bio crushed on poor heart trial results Company: Arca Bio ( ABIO ) Therapy: Buci… read more...
3 Things In Biotech You Should Learn Today: February 27, 2018
via: SeekingAlpha at 2018-02-28 08:00:00:000
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Arca Bio crushed on poor heart trial results Company: Arca Bio ( ABIO ) Therapy: Buci… read more...
Your Daily Pharma Scoop: Progenics Update, La Jolla Data, ARCA Biopharma Setback
via: SeekingAlpha at 2018-02-27 08:00:00:000
Analysis of top Seeking Alpha coverage: Progenics Today we will discuss Progenics Pharmaceuticals ( PGNX ), which last week presented at the RBC Capital Markets Global Healthcare Conference. As we have noted before, Progenics has an important upcoming catalyst, which could provide a si… read more...
Your Daily Pharma Scoop: Progenics Update, La Jolla Data, ARCA Biopharma Setback
via: SeekingAlpha at 2018-02-27 08:00:00:000
Analysis of top Seeking Alpha coverage: Progenics Today we will discuss Progenics Pharmaceuticals ( PGNX ), which last week presented at the RBC Capital Markets Global Healthcare Conference. As we have noted before, Progenics has an important upcoming catalyst, which could provide a si… read more...
Midday Gainers / Losers (2/26/2018)
via: SeekingAlpha at 2018-02-26 12:49:58:000
Gainers: NXTD +30% . TAHO +20% . RCM +20% . ZSAN +18% . TTPH +18% . APLS +16% . XTNT +15% . DTRM +14% . CGEN +14% . ACHN +14% . More news on: NXT-ID Inc., Tahoe Resources Inc., R1 RCM Inc., Stocks on the move, , Read more … read more...
Achillion's ACH-4471 receives positive opinion for ODD in Europe for the treatment of C3 glomerulopathy
via: SeekingAlpha at 2018-02-26 06:50:55:000
Achillion Pharmaceuticals (NASDAQ: ACHN ) announces that the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending Orphan Drug status for ACH-4471 for the treatment of C3 glomerulopathy (C3G). More news on: Achil… read more...
Achillion Pharmaceuticals, Inc. 2017 Q4 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-02-23 13:14:01:000
The following slide deck was published by Achillion Pharmaceuticals, Inc. in conjunction with their 2017 Q4 earnings Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-08 08:39:57:000
Aurinia Pharmaceuticals (NASDAQ: AUPH ) initiated with Outperform rating and $9 (74% upside) price target at RBC Capital Markets. More news on: Aurinia Pharmaceuticals Inc., Achillion Pharmaceuticals, Inc., Spark Therapeutics, Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-08 08:39:57:000
Aurinia Pharmaceuticals (NASDAQ: AUPH ) initiated with Outperform rating and $9 (74% upside) price target at RBC Capital Markets. More news on: Aurinia Pharmaceuticals Inc., Achillion Pharmaceuticals, Inc., Spark Therapeutics, Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-08 08:39:57:000
Aurinia Pharmaceuticals (NASDAQ: AUPH ) initiated with Outperform rating and $9 (74% upside) price target at RBC Capital Markets. More news on: Aurinia Pharmaceuticals Inc., Achillion Pharmaceuticals, Inc., Spark Therapeutics, Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-02-08 08:39:57:000
Aurinia Pharmaceuticals (NASDAQ: AUPH ) initiated with Outperform rating and $9 (74% upside) price target at RBC Capital Markets. More news on: Aurinia Pharmaceuticals Inc., Achillion Pharmaceuticals, Inc., Spark Therapeutics, Healthcare stocks news, Read more … read more...
Stocks To Watch: Guidance Updates All Around
via: SeekingAlpha at 2018-01-13 10:15:28:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Earnings season heats up this week with more big names likely to follow in the path… read more...
Achillion Pharmaceuticals: Ultra-Rare Disease Company With Ultra-Rare Enterprise Value
via: SeekingAlpha at 2018-01-09 11:31:28:000
Background of the Company Achillion ( ACHN ) is a biopharmaceutical company specializing in discovering and developing small molecules for complement-mediated diseases. The complement system is a part of the human innate immune system and is believed to comprise three pathways - the alt… read more...
How I Beat The Market In 2017
via: SeekingAlpha at 2018-01-09 10:19:44:000
Benjamin Graham preached that, if one is to take an active (rather than passive) approach to investing, one must treat it as a business. As someone who has started and helped to run multiple businesses, I understand the commitment this entails. It means spending your time researching as if… read more...
Your Daily Pharma Scoop: Ultragenyx Sells Voucher, Regeneron Announces Collaboration, Madrigal Offering
via: SeekingAlpha at 2017-12-19 08:04:09:000
Content Analysis of coverage: RARE Stocks in the news: REGN, MDGL Analyst Ratings Insider Sales Insider Purchases Earnings Report Secondary Offerings Earnings Calendar Subscriber Questions & Answers (for TPT Subscribers only) Catalyst Rundown (for… read more...
3 Things In Biotech You Should Learn Today: December 19, 2017
via: SeekingAlpha at 2017-12-19 08:00:00:000
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Achillion reports phase 1 data in kidney disease Company: Achillion Pharmaceuticals ( ACH… read more...
Achillion's ACH-4471 granted ODD for the treatment of C3G; initiated Phase 1 extended-release bioavailability study
via: SeekingAlpha at 2017-12-18 07:43:29:000
Achillion Pharmaceuticals (NASDAQ: ACHN ) announces that the FDA has granted Orphan Drug status for ACH-4471 for the treatment of patients with C3 Glomerulopathy (C3G). More news on: Achillion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Achillion CMO to leave this month
via: SeekingAlpha at 2017-12-15 11:27:03:000
Achillion Pharmaceuticals ( ACHN -0.5% ) EVP, Chief Medical Officer David Apelian, M.D., Ph.D. will resign effective December 28 to pursue a position elsewhere. A search for a successor is underway. More news on: Achillion Pharmaceuticals, Inc., Healthcare stocks news, Read more ….. read more...
Akari's Coversin successful in mid-stage PNH study
via: SeekingAlpha at 2017-12-08 16:39:08:000
A Phase 2 clinical trial, COBALT , assessing Akari Therapeutics' (NASDAQ: AKTX ) lead candidate Coversin in patients with paroxysmal nocturnal hemoglobinuria (PNH) met the primary endpoint of a statistically significant reduction in LDH (lactate dehydrogenase) to within 1.8x the upper lim… read more...
After Hours Gainers / Losers
via: SeekingAlpha at 2017-11-24 15:04:46:000
Top gainers: CYTK +3.9% . PAA +3.7% . SOGO +1.7% . REDU +1.2% . ACHN +0.9% . More news on: Cytokinetics, Incorporated, Plains All American Pipeline, L.P., Sogou, Stocks on the move, Read more … read more...
Premarket Gainers as of 9:05 am
via: SeekingAlpha at 2017-11-16 09:26:39:000
CADC +198% . More news on: China Advanced Construction Materials Group, Inc., SemiLEDs Corporation, Time Inc., Stocks on the move, Read more … read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|